You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Skin conditions
  5. Psoriasis

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people

  • Technology appraisal guidance
  • Reference number: TA455
  • Published:  12 July 2017
  • Guidance
  • Tools and resources
  • Information for the public
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 The technologies
  • 3 Evidence
  • 4 Committee discussion
  • 5 Implementation
  • 6 Recommendations for research
  • 7 Appraisal committee members and NICE project team

6 Recommendations for research

6.1

Trials that evaluate utility values (using generic preference-based measures) in children and young people with severe psoriasis are needed to better inform future cost–utility analyses.


Next page 7 Appraisal committee members and NICE project team Previous page 5 Implementation
Back to top